Pharmaceutical - Financial, Humira

Filter

Current filters:

FinancialHumira

Popular Filters

AbbVie issues earnings-per-share guidance up 30% for 2015

AbbVie issues earnings-per-share guidance up 30% for 2015

12-01-2015

US drugmaker AbbVie has issued updated guidance about its expected earnings in 2015.

AbbVieAnti-viralsFinancialHumiraPharmaceuticalUSAViekira Pak

AbbVie, still fuelled by Humira, beats own and analysts’ forecasts

AbbVie, still fuelled by Humira, beats own and analysts’ forecasts

01-11-2014

Just a couple of weeks after abandoning its $54 billion “tax inversion” motivated takeover of Ireland-headquartered…

AbbVieAnti-Arthritics/RheumaticsFinancialHumiraPharmaceuticalShireUSA

AbbVie 2nd-qtr 2014 earnings beat forecasts

25-07-2014

US drugmaker AbbVie, which has just clinched a $55 billion deal to acquire Ireland-based Shire, reported…

AbbVieFinancialHumiraPharmaceutical

Accelerated growth for AbbVie’s Humira lifts 3rd-quarter results above expectation

Accelerated growth for AbbVie’s Humira lifts 3rd-quarter results above expectation

27-10-2013

Shares of AbbVie were up 2.4% at $49.09 in afternoon trading on the New York Stock Exchange on Friday,…

AbbVieFinancialHumiraPharmaceutical

AbbVie beats expectations, as Humira keeps growing

28-07-2013

US drugmaker AbbVie (NYSE: ABBV), spun-out from Abbott Laboratories from the start of this year, reported…

AbbVieFinancialHumiraPharmaceutical

Back to top